Literature DB >> 26439715

Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells.

Paul W Burridge1,2,3, Alexandra Holmström1,2,3, Joseph C Wu1,2,3.   

Abstract

Since the first discovery that human pluripotent stem cells (hPS cells) can differentiate to cardiomyocytes, efforts have been made to optimize the conditions under which this process occurs. One of the most effective methodologies to optimize this process is reductionist simplification of the medium formula, which eliminates complex animal-derived components to help reveal the precise underlying mechanisms. Here we describe our latest, cost-effective and efficient methodology for the culture of hPS cells in the pluripotent state using a modified variant of chemically defined E8 medium. We provide exact guidelines for cell handling under these conditions, including non-enzymatic EDTA passaging, which have been optimized for subsequent cardiomyocyte differentiation. We describe in depth the latest version of our monolayer chemically defined small molecule differentiation protocol, including metabolic selection-based cardiomyocyte purification and the addition of triiodothyronine to enhance cardiomyocyte maturation. Finally, we describe a method for the dissociation of hPS cell-derived cardiomyocytes, cryopreservation, and thawing.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  cardiac; cardiomyocyte; chemically defined; differentiation; human induced pluripotent stem cells; monolayer

Mesh:

Year:  2015        PMID: 26439715      PMCID: PMC4597313          DOI: 10.1002/0471142905.hg2103s87

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  21 in total

1.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.

Authors:  Xiaojun Lian; Cheston Hsiao; Gisela Wilson; Kexian Zhu; Laurie B Hazeltine; Samira M Azarin; Kunil K Raval; Jianhua Zhang; Timothy J Kamp; Sean P Palecek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  Human embryonic stem cell-derived cardiomyocytes can be maintained in defined medium without serum.

Authors:  Chunhui Xu; Jia-Qiang He; Timothy J Kamp; Shailaja Police; Xiaoming Hao; Chris O'Sullivan; Melissa K Carpenter; Jane Lebkowski; Joseph D Gold
Journal:  Stem Cells Dev       Date:  2006-12       Impact factor: 3.272

3.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes.

Authors:  Shugo Tohyama; Fumiyuki Hattori; Motoaki Sano; Takako Hishiki; Yoshiko Nagahata; Tomomi Matsuura; Hisayuki Hashimoto; Tomoyuki Suzuki; Hiromi Yamashita; Yusuke Satoh; Toru Egashira; Tomohisa Seki; Naoto Muraoka; Hiroyuki Yamakawa; Yasuyuki Ohgino; Tomofumi Tanaka; Masatoshi Yoichi; Shinsuke Yuasa; Mitsushige Murata; Makoto Suematsu; Keiichi Fukuda
Journal:  Cell Stem Cell       Date:  2012-11-15       Impact factor: 24.633

4.  Derivation of human embryonic stem cells in defined conditions.

Authors:  Tenneille E Ludwig; Mark E Levenstein; Jeffrey M Jones; W Travis Berggren; Erika R Mitchen; Jennifer L Frane; Leann J Crandall; Christine A Daigh; Kevin R Conard; Marian S Piekarczyk; Rachel A Llanas; James A Thomson
Journal:  Nat Biotechnol       Date:  2006-01-01       Impact factor: 54.908

5.  Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions.

Authors:  Jeanette Beers; Daniel R Gulbranson; Nicole George; Lauren I Siniscalchi; Jeffrey Jones; James A Thomson; Guokai Chen
Journal:  Nat Protoc       Date:  2012-10-25       Impact factor: 13.491

6.  Alternative cultures for human pluripotent stem cell production, maintenance, and genetic analysis.

Authors:  Kevin G Chen; Rebecca S Hamilton; Pamela G Robey; Barbara S Mallon
Journal:  J Vis Exp       Date:  2014-07-24       Impact factor: 1.355

7.  Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability.

Authors:  Paul W Burridge; David Anderson; Helen Priddle; Maria D Barbadillo Muñoz; Sarah Chamberlain; Cinzia Allegrucci; Lorraine E Young; Chris Denning
Journal:  Stem Cells       Date:  2006-12-21       Impact factor: 6.277

8.  What is the point of large-scale collections of human induced pluripotent stem cells?

Authors:  Ruth McKernan; Fiona M Watt
Journal:  Nat Biotechnol       Date:  2013-10       Impact factor: 54.908

9.  Continuous hypoxic culturing of human embryonic stem cells enhances SSEA-3 and MYC levels.

Authors:  Elisa Närvä; Juha-Pekka Pursiheimo; Asta Laiho; Nelly Rahkonen; Maheswara Reddy Emani; Miro Viitala; Kirsti Laurila; Roosa Sahla; Riikka Lund; Harri Lähdesmäki; Panu Jaakkola; Riitta Lahesmaa
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  Chemically defined generation of human cardiomyocytes.

Authors:  Paul W Burridge; Elena Matsa; Praveen Shukla; Ziliang C Lin; Jared M Churko; Antje D Ebert; Feng Lan; Sebastian Diecke; Bruno Huber; Nicholas M Mordwinkin; Jordan R Plews; Oscar J Abilez; Bianxiao Cui; Joseph D Gold; Joseph C Wu
Journal:  Nat Methods       Date:  2014-06-15       Impact factor: 28.547

View more
  56 in total

Review 1.  Tissue-Engineering for the Study of Cardiac Biomechanics.

Authors:  Stephen P Ma; Gordana Vunjak-Novakovic
Journal:  J Biomech Eng       Date:  2016-02       Impact factor: 2.097

2.  Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Vi T Tang; Thomas S O'Leary; Sabrina Friedline; Mick Wauchope; Akul Arora; Aaron H Wasserman; Eric D Smith; Lap Man Lee; Xiaoquan W Wen; Jordan A Shavit; Allen P Liu; Michael J Previs; Sharlene M Day
Journal:  JCI Insight       Date:  2020-01-30

3.  Cardiac Atrophy and Heart Failure In Cancer.

Authors:  Mark Sweeney; Angela Yiu; Alexander R Lyon
Journal:  Card Fail Rev       Date:  2017-04

4.  Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Authors:  Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

Review 5.  Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.

Authors:  Nazish Sayed; Chun Liu; Joseph C Wu
Journal:  J Am Coll Cardiol       Date:  2016-05-10       Impact factor: 24.094

Review 6.  Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development.

Authors:  Kacey Ronaldson-Bouchard; Gordana Vunjak-Novakovic
Journal:  Cell Stem Cell       Date:  2018-03-01       Impact factor: 24.633

Review 7.  Can We Engineer a Human Cardiac Patch for Therapy?

Authors:  Jianyi Zhang; Wuqiang Zhu; Milica Radisic; Gordana Vunjak-Novakovic
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

8.  Controlled Release of Small Molecules for Cardiac Differentiation of Pluripotent Stem Cells.

Authors:  Christopher J Tsao; Francesca Taraballi; Laura Pandolfi; Aaron J Velasquez-Mao; Rodrigo Ruano; Ennio Tasciotti; Jeffrey G Jacot
Journal:  Tissue Eng Part A       Date:  2018-10-29       Impact factor: 3.845

Review 9.  Induced pluripotent stem cells as a platform to understand patient-specific responses to opioids and anaesthetics.

Authors:  Detlef Obal; Joseph C Wu
Journal:  Br J Pharmacol       Date:  2020-08-27       Impact factor: 8.739

Review 10.  Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.

Authors:  Tarek Magdy; Adam J T Schuldt; Joseph C Wu; Daniel Bernstein; Paul W Burridge
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.